Status:
COMPLETED
An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Brief Summary
This study is conducted in Africa and Asia. The aim of this study is to evaluate the efficacy, safety and convenience of using repaglinide (NovoNorm®) in type 2 diabetes management in routine clinical...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Type 2 diabetes
- Newly diagnosed or not adequately controlled with current therapy
Exclusion
Key Trial Info
Start Date :
August 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
30554 Patients enrolled
Trial Details
Trial ID
NCT01498900
Start Date
August 1 2004
End Date
July 1 2006
Last Update
October 28 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Istanbul, Turkey (Türkiye), 34335